Email Sign-up
Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Interviews
Investigator Perspectives
Case-Based Peer Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Specialties >>

Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
HER2- Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Special Reports
Hematologic Malignancies: Polycythemia Vera

Clinical Articles

Significant Developments in Treating PV
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera
Expert Discusses Recent Developments in Polycythemia Vera
Management of ET, PV Requires 2 Distinct Approaches
Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs
Experts Debate Need for New Drugs to Treat Patients with PV and ET
Differences Between Polycythemia Vera and Essential Thrombocythemia
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.